Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.40 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17658728 | 0.88 | KDM4E (0.44) | GSK3BABCG2KDRFLT1KDM4E | |
| SCHEMBL12336431 | 0.87 | KDR (0.54) | GSK3BABCG2KDRBRAFMAPK14 | |
| SCHEMBL12336259 | 0.82 | GSK3B (0.45) | GSK3BKDRBRAFMAPK14NPSR1 | |
| SCHEMBL12336434 | 0.81 | KDR (0.47) | GSK3BKDRBRAFNPSR1ADCY1 | |
| SCHEMBL12336547 | 0.81 | ABCG2 (0.46) | ABCG2KDRBRAFMAPK14L3MBTL1 | |
| SCHEMBL14949499 | 0.80 | PDGFRB (0.44) | GSK3BABCG2KDRBRAFMAPK14 | |
| SCHEMBL17661758 | 0.79 | LMNA (0.47) | GSK3BABCG2KDRBRAFNPSR1 | |
| SCHEMBL12336252 | 0.79 | KDR (0.60) | GSK3BABCG2KDRBRAFMAPK14 | |
| SCHEMBL12336280 | 0.78 | KDR (0.55) | GSK3BKDRBRAFMAPK14NPSR1 | |
| SCHEMBL12336273 | 0.78 | PDGFRB (0.57) | GSK3BABCG2KDRBRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | GSK3B 581/4885ABCG2 1978/4885KDR 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.